These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Recommendations for the development of vaginal microbicides. International Working Group on Vaginal Microbicides. AIDS; 1996 Jul; 10(8):1-6. PubMed ID: 8828760 [TBL] [Abstract][Full Text] [Related]
10. Development of dapivirine vaginal ring for HIV prevention. Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702 [TBL] [Abstract][Full Text] [Related]
11. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Pirrone V; Wigdahl B; Krebs FC Antiviral Res; 2011 Jun; 90(3):168-82. PubMed ID: 21439325 [TBL] [Abstract][Full Text] [Related]
12. [Application studies of animal models in evaluating safety and efficacy of HIV-1 microbicides]. Zhu L; Zhang GH; Zheng YT Dongwuxue Yanjiu; 2010 Feb; 31(1):66-76. PubMed ID: 20446456 [TBL] [Abstract][Full Text] [Related]
13. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760 [TBL] [Abstract][Full Text] [Related]
14. [Improved long-term success. New nucleoside for once daily combinations]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043 [No Abstract] [Full Text] [Related]
15. FAITH - Fast Assembly Inhibitor Test for HIV. Hadravová R; Rumlová M; Ruml T Virology; 2015 Dec; 486():78-87. PubMed ID: 26410239 [TBL] [Abstract][Full Text] [Related]
16. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069 [TBL] [Abstract][Full Text] [Related]
18. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective]. Wepner U MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085 [No Abstract] [Full Text] [Related]
19. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges. Nunes R; Sarmento B; das Neves J J Control Release; 2014 Nov; 194():278-94. PubMed ID: 25229988 [TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of a mucoadhesive polymeric caplet for intravaginal anti-HIV-1 delivery and development of a molecular mechanistic model for thermochemical characterization. Ndesendo VM; Choonara YE; Meyer LC; Kumar P; Tomar LK; Tyagi C; du Toit LC; Pillay V Drug Dev Ind Pharm; 2015; 41(8):1274-87. PubMed ID: 25109400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]